Sagimet Biosciences Inc.
Close on Oct 19, 2026
- Market cap
- $470.59M
- P/E (TTM)
- –
- Dividend yield
- –
About Sagimet Biosciences
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical firm that develops oral therapeutics targeting dysfunctional metabolic and fibrotic pathways. Its research focuses on fatty acid synthase inhibitors designed to treat conditions caused by excess palmitate production. Its primary drug candidate is denifanstat, an oral daily medication being evaluated for metabolic dysfunction-associated steatohepatitis, moderate to severe acne, and specific forms of cancer. Its secondary pipeline asset is TVB-3567, a small molecule candidate also aimed at treating acne. The company designs its therapies for patients suffering from liver disease, dermatological disorders, and solid tumors, and it works with commercial biopharmaceutical partners such as Ascletis to advance programs in designated territories.
The enterprise holds a proprietary library containing over 1,200 discovered compounds. Its clinical activities and collaborative clinical trials take place across the United States and Greater China, where partner-led Phase 3 trials involve hundreds of patients across multicenter sites. The provided text does not identify the location of the company's corporate headquarters.
Summary of the business section of Sagimet Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sagimet Biosciences Inc.
- Headquarters
- Foster City, CA
- Address
- 950 Tower Lane, Ste 1500 94404
- Phone
- (650) 561-8600
- Website
- sagimet.com
- Employees
- 16, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, California
Stock & identifiers
- Ticker
- SGMT
- Exchange
- Nasdaq
- IPO date
- Jul 14, 2023
- Shares outstanding
- 62M, Aug 4, 2026
- Public float
- $228.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1400118
- CUSIP
- 786700104
- ISIN
- US7867001049
- LEI
- 2549002OT2F8BV0VPD02
- EIN
- 20-5991472
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Happel | President & CEO, Director | 741,570 |
| Elizabeth Rozek | Chief Legal & Admin. Officer | 224,414 |
| Andreas Grauer | Chief Medical Officer | – |
| Thierry Chauche | Chief Financial Officer | 59,688 |
| Eduardo Bruno Martins | Chief Medical Officer | 147,296 |
| George Kemble | Director | 62,161 |
| Elizabeth A. Grammer | Director | – |
| Beth C. Seidenberg | Director | 131,643 |
| Jennifer Jarrett | Director | – |
| Paul W. Hoelscher | Director | – |
| Anne M. Phillips | Director | – |
| Timothy P. Walbert | Director | 2,200 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 16 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 22, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 11, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Feb 25, 2019 | Name change | Name changed from 3-V Biosciences, Inc. to Sagimet Biosciences Inc. |